Brokers Set Expectations for TARS FY2030 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities researchers at HC Wainwright issued their FY2030 earnings per share estimates for shares of Tarsus Pharmaceuticals in a report issued on Tuesday, February 24th. HC Wainwright analyst M. Caufield expects that the company will earn $6.36 per share for the year. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.73% and a negative net margin of 14.72%.

Several other research analysts have also recently weighed in on TARS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. The Goldman Sachs Group restated a “neutral” rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Barclays initiated coverage on Tarsus Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $100.00 price target on the stock. Wall Street Zen raised Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Mizuho started coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.29.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock opened at $75.01 on Wednesday. Tarsus Pharmaceuticals has a 1-year low of $38.51 and a 1-year high of $85.25. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $3.18 billion, a PE ratio of -46.30, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The firm’s 50 day simple moving average is $72.25 and its 200 day simple moving average is $68.35.

Insider Activity

In related news, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the transaction, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This trade represents a 0.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Dianne C. Whitfield sold 7,397 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the sale, the insider owned 38,958 shares of the company’s stock, valued at $3,120,535.80. The trade was a 15.96% decrease in their position. The SEC filing for this sale provides additional information. 8.97% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently made changes to their positions in TARS. Invesco Ltd. raised its position in Tarsus Pharmaceuticals by 8.0% in the 4th quarter. Invesco Ltd. now owns 1,012,357 shares of the company’s stock worth $82,892,000 after purchasing an additional 75,351 shares during the period. Mackenzie Financial Corp bought a new position in shares of Tarsus Pharmaceuticals during the fourth quarter valued at about $202,000. XTX Topco Ltd increased its holdings in shares of Tarsus Pharmaceuticals by 270.3% in the fourth quarter. XTX Topco Ltd now owns 18,410 shares of the company’s stock worth $1,507,000 after buying an additional 13,438 shares during the period. Squadron Capital Management LLC bought a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $6,550,000. Finally, Tudor Investment Corp ET AL purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at about $1,859,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Key Stories Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Management guided 2026 revenue to $670M–$700M and reiterated XDEMVY’s potential for $2B+ peak sales, a major growth catalyst that supports higher valuation and investor optimism. Tarsus expects $670M–$700M 2026 sales as XDEMVY eyes blockbuster $2B+ potential while pipeline advances
• Positive Sentiment: Q4/FY2025 topline strength: FY2025 revenue jumped ~150% to $451M, Q4 sales beat consensus ($151.7M vs ~$144.6M), and management forecasts high gross margins (~93%) — signals of rapid commercial traction for XDEMVY and margin leverage ahead. Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential
• Neutral Sentiment: Management provided detailed commentary on international rollout timing (China 2026, Europe 2027) and commercial planning on the earnings call; these expand the TAM but will take time to convert into near-term revenue. Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Company posted a formal press release and slide deck summarizing Q4 results and strategic milestones — useful for investors modeling rollout assumptions and margin expansion. Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
• Negative Sentiment: GAAP EPS missed by $0.01 (reported -$0.20 vs. consensus -$0.19) and the company remains unprofitable with negative net margin and ROE; management now expects profitability in 2027, which delays cash-flow conversion risk. Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.